ClinicalTrials.gg
CompletedNCT04625088Updated Feb 3, 2022

Identification of Biometric Marker(s) Capable of Detecting Early Prediabetes: Clinical Trial 1

An interventional study of Standardized liquid test meal and Atropine + Standardized liquid test meal in Healthy, sponsored by SciMar Ltd.. Completed at 1 site in Canada. Open to participants aged 20 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-03.

Sponsored by SciMar Ltd. · Not applicable, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
20 Years to 40 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 197 studies in Insulin Resistance with a site in Canada — 21 open to participants now, 27 under way, 4 of them phase 3. Insulin Resistance · Canada.

Enrollment
100th of 172
24 · median 30
Started
2021
with 4 others
No phase
94 of 197
12 open now
Registered
157th of 197
by date

Among the 197 studies in Insulin Resistance with a site in Canada, this one is the 100th largest by enrollment of the 172 interventional ones that give a count, is one of 5 that started in 2021, is one of 94 with no phase, and was the 157th registered.

Insulin Resistance

2,972 studies on the registry are indexed under Insulin Resistance; 337 are open to participants now.

Browse Insulin Resistance studies →

Open to participants now

21 of the 197 studies in Insulin Resistance with a site in Canada are open now. Recruiting first, the newest first:

16 more — sign in →

All 21 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 244 Insulin Resistance studies recruiting now, 54 (22%) set no upper age limit and 158 (65%) stop at 75 or younger; 30 take children under 18; 113 take healthy volunteers.

This study: 20 Years to 40 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies in Insulin Resistance with a site in Canada, or all of them as a file.
02

Study summary

The proposed clinical trial is a controlled study of n=24 healthy adult individuals tested in both the Meal-Induced Insulin Sensitization (MIS) state and, following atropine blockade, Absence of Meal-Induced Insulin Sensitization (AMIS) state to differentiate the postprandial glycemia, insulinemia, triglyceride and Hepatic Insulin Sensitizing Substance (HISS) levels in the two states.

The purpose of this study is the identification and development of biometric markers which incorporate the actions and interplay between insulin and HISS. Overall, the study aims to:

  1. Utilize a standardized test meal to detect one of the earliest pathologies present during the development of insulin resistance, pre-diabetes and obesity.
  2. Compare the control (HISS positive) and post-atropine (HISS negative) tests with the acute consequences of absence of MIS (AMIS) being graphically shown over 4 hours of postprandial nutrient partitioning, tracking the full metabolomic dynamic pattern.
  3. To establish values for potential indices (bio-impedance, hand-grip strength, spirometry) in young, fit, lean individuals. These values will be used as baselines for comparative analysis in future clinical trials employing individuals with various degrees of insulin resistance to full Type 2 Diabetes.
  4. Demonstrate that these biometric markers can differentiate between the HISS positive and HISS negative post-meal state with the future aim of using the biomarkers for the detection of early prediabetes.

The study will involve 4 study visits: Visit 1 - Prescreening; Visit 2 - Screening; Visit 3 - Liquid test meal administration and postprandial blood collection; Visit 4 - Atropine administration + Liquid test meal administration and postprandial blood collection.

03

Conditions studied

  • Healthy

Keywords

  • Glucose; Insulin; Prediabetes
04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy (absence of disease)
  • Not on any prescribed medications
  • Male and female (in follicular phase)
  • 20-40 years of age
  • Normal range (18.5-24.9)
  • Able to understand and communicate in English
  • Comfortable having blood drawn
  • Willing to provide urine and blood samples
  • Normal urinalysis, Complete Blood Count (CBC) and blood chemistry laboratory test results
  • Willingness to undergo bioimpedance testing, handgrip dynamometry (strength) testing, and pulmonary function test (spirometry).
  • Willingness to undergo atropine administration
  • Willingness to fast for 12 hours prior to the screening and testing days
  • Willingness to undergo (ECG) and Heart Rate Variability (HRV) testing
  • Willingness to use non-hormonal methods throughout the study duration

Exclusion criteria

Exclusion Criteria:

  • Glaucoma, Pyloric Stenosis
  • Obstructive Uropathy, Urinary Incontinence
  • Diabetes, Cardiovascular Disease, including Heart Murmurs
  • Diagnosed or with history (last 6 months) and receiving pharma or professional therapy for Psychological/Psychiatric issues
  • Inflammatory conditions, including IBD
  • Subject on any hormone treatment, including thyroid hormone
  • Subject on any therapy including cortisol, or any anti-inflammatory agent
  • Sensitivity to anti-cholinergic drugs
  • Allergic or have sensitivities to rubbing alcohol during blood draw
  • Allergy/sensitivity to any component of the standardized test meal (dextrose, lecithin, soy protein)
  • Pregnant women, women of not willing to use barrier method , women trying to get pregnant, and breastfeeding women, women using hormonal birth control
  • Whole blood donation (50-499 ml of whole blood) within 30 days, and more than 499 ml of whole blood 56 days prior to test visit 1. Participants should not donate whole blood for the duration of the trial, and for 30 days following the end of the trial
  • Blood pressure greater than 140/90 mmHg and heart rate greater than or equal to 80 beats per minute
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Standardized liquid test meal

    Other: Standardized liquid test meal

  • Experimental
    Atropine + Standardized liquid Test meal

    Drug: Atropine + Standardized liquid test meal

Interventions

  • OtherStandardized liquid test meal

    During this study visit, a standardized liquid test meal will be administered. Blood samples will be collected at baseline and then every 30 minutes for 4 hours after test meal.

  • DrugAtropine + Standardized liquid test meal

    During this study visit, 1.0 mg atropine will be administered I.V and then a standardized liquid test meal will be administered. Blood samples will be collected at baseline, following atropine administration, and then every 30 minutes for 4 hours after test meal.

06

What researchers measure

Primary outcomes

  1. Time course change in serum glucose

    Time course and curve analysis of serum glucose response after the test meal administration with and without atropine pre-treatment.

    Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

  2. Time course change in serum insulin

    Time course and curve analysis of serum insulin response after the test meal administration with and without atropine pre-treatment

    Time frame: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

  3. Time course change in serum triglycerides

    Time course and curve analysis of serum triglycerides response after the test meal administration with and without atropine pre-treatment

    Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

  4. Time course change in plasma HISS levels

    Time course and curve analysis of plasma HISS response after the test meal administration with and without atropine pre-treatment

    Time frame: Time Frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

Secondary outcomes

  1. Time course change in serum free fatty acids

    Time course and curve analysis of serum free fatty acid response after the test meal administration with and without atropine pre-treatment

    Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

  2. Time course change in plasma lactate

    Time course and curve analysis of plasma lactate response after the test meal administration with and without atropine pre-treatment

    Time frame: Control: Baseline, and every 30 minutes up to 4 hours after test meal administration; Test: Baseline, 15 mins post atropine and every 30 minutes up to 4 hours after test meal administration

  3. Time frame fasted HOMA-IR (Molar Units)

    Time frame HOMA-IR, calculated using the formula: fasting insulin (mIU/L) X fasting glucose (mmol/L)

    Time frame: Control: Baseline fasted Test: 15 mins post atropine

  4. Time course change in Meal Induced Glycemia (MIG) scores (Molar Units)

    Time course and curve analysis of Meal Induced Glycemia (MIG) scores response after the test meal administration with and without atropine pre-treatment. MIG is calculated using the formula: MIG = (post meal insulin mIU/L X post meal glucose mmol/L) minus (fasted insulin mIU/L X fasted glucose mmol/L). Higher score equates to a worse (unhealthy) outcome

    Time frame: Control: Every 30 minutes up to 4 hours after test meal administration; Test: Every 30 minutes up to 4 hours after test meal administration

07

Study locations

1 site
  • Kalo Medical Clinic
    Winnipeg, Manitoba R2K 3Z5, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Aug 2021, 5 months.

Of 40 industry-sponsored interventional studies with no phase under Insulin Resistance, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 22. This study's 5 months is below that.

Counting every sponsor, half of 757 studies reached it within 21 months; a quarter within 9 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2020
First posted
Nov 12, 2020
StartActual
Mar 1, 2021
Primary completionActual
Aug 6, 2021
CompletionActual
Aug 6, 2021
Last update
Feb 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04625088
Lead sponsor
SciMar Ltd.
Collaborators
Source Nutraceutical, Inc.
Responsible party
Sponsor
First posted
Nov 12, 2020
Start date
Mar 1, 2021
Primary completion
Aug 6, 2021
Completion
Aug 6, 2021
Last update
Feb 3, 2022

Study contacts

Vanu Ramprasath, PhD
principal investigator · Source Nutraceutical, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion